Understanding why some lymphomas resist T-cell therapy
Determinants of Resistance to Engineered T-cell Therapies Targeting CD19 in Lymphoma
This work aims to understand why a promising T-cell treatment for a type of lymphoma called large B-cell lymphoma doesn't always work for patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11329019 on NIH RePORTER |
What this research studies
For patients with large B-cell lymphoma that has come back or not responded to initial treatments, CAR T-cell therapy targeting CD19 has shown great promise. However, more than half of these patients still experience their disease getting worse. We are looking into the reasons why this resistance happens and what factors might predict a poor outcome. By studying blood samples from patients, we hope to uncover these mechanisms and use this knowledge to design even better immune therapies in the future.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with large B-cell lymphoma who have received or are considering CAR T-cell therapy.
Not a fit: Patients with other types of cancer or those not undergoing CAR T-cell therapy for large B-cell lymphoma may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new and improved T-cell therapies that are more effective for patients with large B-cell lymphoma.
How similar studies have performed: While CAR T-cell therapy has shown success in many patients, the specific mechanisms of resistance are not yet well understood, making this a novel area of focus.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Sworder, Brian — Beckman Research Institute/city of Hope
- Study coordinator: Sworder, Brian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.